Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

Impact · against what's priced in

Soleno Therapeutics faces critical threats to its flagship drug, VYKAT XR, as allegations of heart failure risks and trial data integrity issues emerge. The confirmation of launch disruptions and the subsequent securities class action create a significant overhang on the company's commercial viability.

SLNO−0.90

No priced-in read yet